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Feasibility and Pilot studies 
This is a definition that has been agreed by the Efficacy and Mechanism Evaluation (EME), 
Public Health Research (PHR), Health Technology Assessment (HTA) and Research for 
Patient Benefit (RfPB) Programmes.  
We expect that when pilot or feasibility studies are proposed by applicants, or specified in 
commissioning briefs, a clear route of progression criteria to the substantive study will be 
described. Listing clear progression criteria will apply whether the brief or proposal describes 
just the preliminary study or both together. Whether preliminary and main studies are funded 
together or separately may be decided on practical grounds. 
 
Feasibility studies 
Feasibility Studies are pieces of research done before a main study in order to answer the 
question “Can this study be done?”. They are used to estimate important parameters that 
are needed to design the main study. For instance: 
o standard deviation of the outcome measure, which is needed in some cases 
to estimate sample size;  
o willingness of participants to be randomised;  
o willingness of clinicians to recruit participants;  
o number of eligible patients; carers or other appropriate participants; 
o characteristics of the proposed outcome measure and in some cases 
feasibility studies might involve designing a suitable outcome measure;  
o follow-up rates, response rates to questionnaires, adherence/compliance 
rates, ICCs in cluster trials, etc. 
o availability of data needed or the usefulness and limitations of a particular 
database; and 
o time needed to collect and analyse data. 
Feasibility studies for randomised controlled trials may not themselves be randomised. 
Crucially, feasibility studies do not evaluate the outcome of interest; that is left to the main 
study. 
If a feasibility study is a small randomised controlled trial, it need not have a primary 
outcome and the usual sort of power calculation is not normally undertaken. Instead the 
sample size should be adequate to estimate the critical parameters (e.g. recruitment rate) to 
the necessary degree of precision. 
 Pilot studies 
Pilot studies are a version of the main study that is run in miniature to test whether the 
components of the main study can all work together. It is focused on the processes of the 
main study, for example to ensure recruitment, randomisation, treatment, and follow-up 
assessments all run smoothly. It will therefore resemble the main study in many respects, 
including an assessment of the primary outcome. In some cases this will be the first phase of 
the substantive study and data from the pilot phase may contribute to the final analysis; this 
can be referred to as an internal pilot. Or at the end of the pilot study the data may be 
analysed and set aside, a so-called external pilot. 
 
Feasibility and pilot studies: which programme should I apply to? 
There are a number of NIHR programmes which will fund feasibility and pilot studies. There 
are no strict rules about which programme funds which feasibility or pilot study and it is for 
applicants to choose the most appropriate in the context of the guidance on applicability 
provided on the webpages for each programme. Nevertheless, in choosing you might like to 
consider the following: 
1. Is the programme appropriate in terms of geography and grant size (RfPB funding, 
for example, can only be accessed through NHS bodies and other providers of NHS 
services in England and has a maximum grant size of £350,000)?  
2. Can a robust case be made for the plausibility of the intervention and clinical 
importance of any subsequent full trial?  If there is good proof of concept and/or 
efficacy data available and there is a clear plan to explore the intervention further in a 
large clinical trial, then HTA or EME might be considered the latter in particular if 
there are substantial mechanistic elements and laboratory support involved in the 
project.  On the other hand, if the feasibility or pilot study is for a potential trial which 
might be viewed as more speculative, with no clear plan for a large trial in the very 
near future, or in which there seems a high risk that the pilot/feasibility study is likely 
to demonstrate that a full trial is not possible, then the smaller sums that RfPB 
provide might be seen as more appropriate.   
Note that feasibility and pilot studies should be distinguished from Phase II trials, in which 
some sort of evidence for efficacy, often in a surrogate marker, is sought prior to embarking 
on a full Phase III trial: EME might be the most appropriate funding stream for these if there 
is strong scientific interest in the question, and RfPB if there is a clear potential trajectory into 
patient benefit.   
The PHR Programme also funds feasibility and pilot studies within its remit of evaluating 
public health interventions delivered outside the NHS.  
  
RfPB 
Guidance on applying for feasibility studies 
Clinical trials are expensive and the chances of successful completion are improved if it can 
be shown beforehand that key elements (such as the ability to recruit patients) are feasible 
before the main study starts. The RfPB Programme will therefore fund such feasibility 
studies which are investigations carried out before a main study in order to answer the 
question “Can this study be done?”. The research plan for a feasibility study should therefore 
contain a brief outline of the proposed main study and a list of the ‘uncertain’ important 
parameters that that are needed to design the main study, as described below. 
The Research Plan section of the application form should include: 
1. A brief outline of the intended main trial. 
Some of these details will of course depend on the results of the proposed feasibility 
research but a key part of evaluating the value of a feasibility study is whether or not a full 
trial is likely to get funded.  You should therefore briefly describe as far as you can what the 
main trial would look like.  This might include (if they are known), whether an individual 
patient randomised or cluster trial, the number of arms, the inclusion criteria, the nature of 
the intervention and of the comparator in the control group, the primary endpoint, and the 
possible range of clinical sites from which patients would be recruited. 
2. A list of the parameters which the feasibility study intends to clarify or estimate. 
These may include: 
• the number of eligible patients, carers or other appropriate participants; 
• an exploration of different methods of identifying/recruiting patients; 
• the willingness of clinicians to recruit and randomise participants; 
• the willingness of participants to be randomised;  
• the practicality of delivering the intervention(s) in the proposed setting(s); 
• variation in use or delivery of the intervention in each setting; 
• acceptability of the intervention to the users; 
• standard deviation of the outcome measure, which is needed in some cases to 
estimate sample size; 
• follow-up rates, response rates to questionnaires, adherence/compliance rates, ICCs 
in cluster trials, etc; 
• availability of data needed or the usefulness and limitations of a particular database;  
• the time needed to collect and analyse data; 
• exploring the opportunities for PPI (patient and public involvement) in the research 
design and its subsequent conduct. 
In effect the research plan should describe which parameters are to be estimated and how 
these will be investigated. 
 
3. A feasibility study does not necessarily need to include the following: 
• a randomised design: the design will be determined by how it is proposed to reduce 
the uncertainty in the parameters described above 
• an evaluation of the outcome of interest: that is left to the main study 
• a primary outcome: if a feasibility study involves carrying out a small randomised 
controlled trial it is for the purpose of evaluating/testing trial processes not the 
intervention 
• the usual sort of power calculation: the sample size should be adequate to estimate 
the critical parameters (e.g. recruitment rate) to the necessary degree of precision 3. 
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